StockNews.AI
FBLG
StockNews.AI
130 days

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

1. FBLG's CSO will present at The Cell & Gene Meeting On The Med. 2. Presentation focuses on fibroblast cell-based therapies for chronic diseases. 3. FBLG holds over 240 patents for chronic disease treatments. 4. The event connects leaders in Advanced Therapy Medicinal Products. 5. Breakthroughs in fibroblast therapies could attract significant investor interest.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive news about FBLG's innovative therapies may boost investor confidence, similar to past biotech presentations that led to stock surges.

How important is it?

The article highlights a key presentation that may stimulate stock activity and public interest in FBLG's innovations.

Why Short Term?

The upcoming presentation could lead to immediate investor interest and stock price movements, akin to previous successful biotech events.

Related Companies

CRISSGENADPT
April 11, 2025 08:30 ET  | Source: Fibrobiologics, Inc. HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond. Details of the conference and presentations are as follows: The Cell & Gene Meeting On The Med Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics Location: Salone dei Cavalieri, Section 2 Date and Time: Wednesday, April 16 at 9:00 AM CEST For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com. General Inquiries:info@fibrobiologics.com Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@russopr.com Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com

Related News